1-3 of 3
Zheng Yuan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Zonder A Jeffrey, MD, Vishal Kukreti, MD FRCPC, Stefan O Schoenland, MD, Arnaud Jaccard, MD, Angela Dispenzieri, MD, Adam D. Cohen, MD, Deborah Berg, RN, MSN, Zheng Yuan, PhD, Ai-Min Hui, MD PhD, Palladini Giovanni, MD PhD, Raymond L. Comenzo, MD
Journal: Blood
Blood (2014) 124 (21): 3450.
https://doi.org/10.1182/blood.V124.21.3450.3450
Published: 2014
Journal Articles

Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study.

Irene M Ghobrial, Jean-Luc Harousseau, Steven P Treon, Brianna Harris, Courtney E Lin, Zheng Yuan, Karim Benhadji, James E Wooldridge, Veronique Leblond
Journal: Blood
Blood (2009) 114 (22): 3867.
https://doi.org/10.1182/blood.V114.22.3867.3867
Published: 2009
Journal Articles

A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.

Irene M Ghobrial, Nikhil C Munshi, Brianna N Harris, Zheng Yuan, Nichole M Porter, Robert L Schlossman, Jacob P Laubach, Kenneth C. Anderson, Courtney E Lin, James E Wooldridge, Paul G Richardson, Rafat Abonour
Journal: Blood
Blood (2009) 114 (22): 1870.
https://doi.org/10.1182/blood.V114.22.1870.1870
Published: 2009